Slide 1: Corporate Deck July 2026
NYSE American:VNRX Corporate Deck July 2026 Property of Volition© 2026 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncer
Slide 3: Recent Achievements
Recent Achievements • Cat Paper Submitted; if published a $5 million contractual milestone payment expected • Fujifilm Vet Systems launch on automated i10 platform • Expansion into non-sepsis disease areas • Mayo Clinic Publication in Trauma. PLUS automated platform installation in Q3 2026 • KOL Pre
Slide 4: Executive Summary
Executive Summary Our mission is to save lives and improve outcomes for millions of people and animals worldwide. VolitionRx NYSE American: VNRX Medical Devices IP Powerhouse Focus Licensing IP Cancer, Sepsis Low-cost testing Commercial Worldwide Animal $23M in licensing $1.4M of Rev H1 26 Large Unm
Slide 5: Working at the Cutting Edge of Epigenetics
Working at the Cutting Edge of Epigenetics Measuring chromatin fragments Cancer NETs Global Experts in Quantifying Nucleosomes Property of Volition© 2026 Slide 5
Slide 6: Low-cost routine tests
Low-cost routine tests Platform agnostic; can be adapted to any diagnostic workflow Six 45 <10 6Hours hours 45 minutes <15 minute <10 minutes minutes <15 minutes minutes s Manual Automated Point of Care Lateral Flow Asset light - no need for own machines, labs or sales reps Property of Volition© 202
Slide 7: Commercialization
Commercialization Property of Volition© 2026 Slide 7
Slide 8: Commercialization Strategy
Commercialization Strategy Underlying principles: low capex, low opex business model focused on commercial partnerships and out- licensing R&D • R&D conducted by Volition and its research partners • Monetize IP through licensing agreements with: • upfront payments, • milestone payments, • recurring
Slide 9: Commercial Validation
Commercial Validation Case Studies: Antech (formerly HESKA Corporation and Fujifilm Vet Systems • Exclusive Element i+ in-house analyzer First Nu.Q® Vet Cancer Test Automation! licensing partnership Immunodiagnostic Systems (IDS) i10® • $10M upfront and $13M Milestone Payments automated analyzer pla
Slide 10: Recent Deals Signed
Recent Deals Signed • Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") for Nu.Q® NETs • Co-Marketing and Services Agreement for Nu.Q® Discover • Collaboration to optimize Nu.Q® NETs assay in diseases associated with NETosis Property of Volition©
Slide 11: Products
Products Property of Volition© 2026 Slide 11
Slide 12: Powered by Nu.Q
Powered by Nu.Q® 74 patents granted with coverage up to 20441 TAM2 Regulation Product Status Strategy Screening/ Reimbursement Sales & $4Bn Lab Developed Management Submission Licensing Multi-Cancer Proof of Sales & $23Bn CE Mark/ FDA Early Detection Concept Licensing >$3Bn First sales Sales & CE Ma
Slide 13: Nu.Q Vet
Nu.Q® Vet Now Available in the North America, Europe, and Asia • Developed to be ACCURATE (detects 76% of systemic cancers at 97% specificity1) • Low cost, as little as $35 to veterinarian (we get $5-$13/test) • Recommended for older dogs and those breeds at increased risk (25M dogs in US alone2) De
Slide 14: Vet Licensing & Supply Agreements to-date
Vet Licensing & Supply Agreements to-date Now Available in the North America, Europe, and Asia • U.S. • Japan • U.S. / Canada / Aus / HK / Singapore & some EU countries • Poland • Portugal • Taiwan • UK & IRE Property of Volition Veterinary Diagnostics Development© 2026 Slide 14
Slide 15: Cancer: Nu.Q addresses all five applications of a blood test in lung cancer
Cancer: Nu.Q® addresses all five applications of a blood test in lung cancer • Reimbursement Dossier in preparation with support of HCL • Expected direct sales for routine clinical use starting in France thereafter • In discussions to license out Nu.Q® Cancer with large liquid biopsy companies Prope
Slide 16: A world first in isolating 99% pure tumor-associated DNA
A world first in isolating 99% pure tumor-associated DNA in cancer patients from a liquid biopsy1 • World first isolation of transcription factor-DNA from blood • World first preparation of tumor-associated DNA sequence data sets • A novel class of thousands of new biomarkers • Compelling proof of c
Slide 17: Neutrophil Extracellular Traps (NETs)
Neutrophil Extracellular Traps (NETs) • produced by ejecting chromosomal material out of the cell1 • catch and kill bacteria and viruses1 • excessive or inadequately resolved NETs are implicated in the underlying pathophysiology of sepsis and other inflammatory diseases1 • first reported in 20042now
Slide 18: Sepsis Unmet Needs
Sepsis Unmet Needs The risk of death from sepsis increases by 7.6% for each hour of delay in appropriate antibiotic therapy1 Current diagnosis is empirical, multi-factorial and subjective CURRENT methods of assessment are complex & slow x Accepted need for improved diagnostics2 1 in 5 deaths worldwi
Slide 19: Volition Nu.Q NETs. H3.1 evidence base 2020 to 2026
Volition Nu.Q® NETs. H3.1 evidence base 2020 to 2026 Basic science, models and assay above the line. Sepsis cohorts below the line. Beyond sepsis bottom row. 2023. Garcia et 2023. Cayford et 2024. Zukas et al. 2024. Atteberry et 2025. Retter, 2025.Cayford et al 2026. Cayford et al. 2025. Wargnies et
Slide 20: DETECSEPS: Government-Backed Program
DETECSEPS: Government-Backed Program • Real-World Evaluation of EARLY Sepsis Detection • Combination of Clinical Score (NEWS2) and Nu.Q® NETs as the sole biomarker • Financed by the French Government (~$7.3 million) • On track for first patient Q3 2026 Property of Volition© 2026 Slide 20
Slide 21: NETs: Casting a new light on sepsis management
NETs: Casting a new light on sepsis management Satellite Symposium at ESICM LIVES 2024 Prof. Djillali Annane Professor of Medicine, University Paris Saclay-UVSQ, France “As a Critical Care Consultant, I see the devastating effects of this disease each day. I believe Nu.Q® NETs, as a diagnostic tool,
Slide 22: Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients • Highly correlated our established automated Nu.Q® NETs test in critically ill sepsis patients1 • Expands use-cases beyond centralized laboratory testing • Materially reduces barriers to testing patients and facilitates nucleosome measuremen
Slide 23: Nu.Q NETs in Acute and Chronic Conditions
Nu.Q® NETs in Acute and Chronic Conditions • Peer-reviewed publication with the Mayo Clinic for use in Trauma. Automated platform installation in Q3 2026 • HS paper available on preprint • APS study underway with Werfen Property of Volition© 2026 Slide 23
Slide 24: Summary
Summary Property of Volition© 2026 Slide 24
Slide 25: Projected Catalysts
Projected Catalysts Multiple licensing deals in 2025 and 2026 Catalyst 2025 2026 2027 Licensing cancer technology Reimbursement / Adoption into routine clinical practice Adoption into national program(s) Licensing Multi-Cancer Early Detection Licensing for Human NETosis / Sepsis Sales of CE marked p
Slide 26: Volition Highlights
Volition Highlights Multiple products already launched Proven Licensing model, validated in Vet Strong IP Multiple multi-billion TAM markets Low-cost, scalable platform with high margins Asset light - no need for own machines, labs, or sales reps In confidential licensing discussions with more than
Slide 27: Appendix
Appendix Property of Volition© 2026 Slide 27
Slide 28: Cancer Studies at Centers of Excellence
Cancer Studies at Centers of Excellence Study Country Cohort Size Key Results Status NucleoCircan France 628 subjects • identify additional 23% of patients that have MRD over ctDNA alone Published • Supports clinical decision to continue first line treatment or change treatment NTU Lung Taiwan 806 p
Slide 29: NETs Studies at Centers of Excellence
NETs Studies at Centers of Excellence Study Country Description Cohort Size Status Amsterdam Netherlands Retrospective analysis of prospectively 1,713 intensive care Published. UMC collected cohort patients Multiple timepoints SISPCT Germany Retrospective analysis of prospectively 971 intensive care